Ultimately, our study extended the phenotypic and genetic spectrum of POMT2-associated LGMDR14 and provided valuable insights into subsequent accurate diagnosis and potential treatment strategies for alpha-dystroglycanopathies. The gene discussed is POMT2; the disease is neuromuscular disease caused by qualitative or quantitative defects of alpha-dystroglycan.